iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment

3 years ago

Multiple leading institutions leverage the versatility of Xoft electronic brachytherapy (eBx) to increasingly treat multiple cancersNASHUA, N.H., April 05, 2022…

Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy

3 years ago

STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence…

Radius Provides Agenda for Today’s R&D Webcast

3 years ago

Focus: RAD011, an investigational synthetic cannabidiol oral solutionWebcast details: 10:00am to 12:00pm for current or prospective investors and sell side…

OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

3 years ago

Interim analysis performed with initial 150 U.S. patient samples enrolled in its prospective multicenter trial for the Unyvero UTI panel…

Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference

3 years ago

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for…

Jushi Holdings Inc. Announces Participation in Upcoming Conferences and Events in April 2022

3 years ago

BOCA RATON, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),…

Dentsply Sirona to Host First Quarter Conference Call on May 5th

3 years ago

CHARLOTTE, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that the Company will be hosting an…

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

3 years ago

LTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative…

Avicanna Expands its Derma-Cosmetics Brand Pura H&W™ into the European Union through a Partnership with Bio-Gate AG

3 years ago

Brand Pura H&W™ Brand Pura H&W™The exclusive distribution agreement includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio The products…

Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting

3 years ago

REHOVOT, Israel, April 05, 2022 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based…